Possible Benefits of Curcumin Regimen in Combination With Taxane Chemotherapy for Hormone-Refractory Prostate Cancer Treatment

被引：18

作者：

Cabrespine-Faugeras, Aurelie ^{[2
]}

Bayet-Robert, Mathilde ^{[1
]}

Bay, Jacques-Olivier ^{[2
]}

Chollet, Philippe

Barthomeuf, Chantal ^{[3
]}

机构：

[1] Ctr Jean Perrin, Unite Rech Clin, Fac Pharm, F-63011 Clermont Ferrand, France

[2] Hop Hotel Dieu, Clermont Ferrand, France

[3] Lab Pharmacognosie & Biotechnol, Clermont Ferrand, France

来源：

NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL | 2010年 / 62卷 / 02期

关键词：

NF-KAPPA-B; ENDOTHELIAL GROWTH-FACTOR; IN-VIVO; DOWN-REGULATION; CELL-SURVIVAL; GENE-PRODUCTS; ENCAPSULATED CURCUMIN; MULTIDRUG-RESISTANCE; MOLECULAR-MECHANISMS; TUMOR-GROWTH;

D O I：

10.1080/01635580903305383

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Complementary and alternative therapies for neoplastic diseases treatment and prevention receive increasing attention from the medical community. Prostate cancer (PC) is the most frequently diagnosed malignancy and the second major cause of male death in industrialized countries. The chemopreventive properties and clinical safety of curcumin, a polyphenolic derivative, have already been established. However, curcumin regimen value in addition to conventional hormone refractory (HR) PC treatment remains largely unknown. This review article summarizes mechanisms by which curcumin may decrease HRPC aggressive proliferation and potentiate activity of taxane therapy. Our analysis suggests that curcumin alone has a therapeutic value in HRPC. In combination with a taxane agent, this compound may enhance cytotoxicity and retard PC cell resistance to taxane. As a consequence, a rationale is provided for considering the possible benefits of curcumin regimen in combination with taxane therapy in HRPC patients.

引用

页码：148 / 153

页数：6

共 64 条

[1]

Aggarwal BB, 2003, ANTICANCER RES, V23, P363

[2] Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IκBα kinase and Akt activation [J].

Aggarwal, S ;

Ichikawa, H ;

Takada, Y ;

Sandur, SK ;

Shishodia, S ;

Aggarwal, BB .

MOLECULAR PHARMACOLOGY, 2006, 69 (01) :195-206

[3] PHARMACOLOGY OF CURCUMA-LONGA [J].

AMMON, HPT ;

WAHL, MA .

PLANTA MEDICA, 1991, 57 (01) :1-7

[4] Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-κB and the serine/threonine kinase Akt and is independent of tubulin polymerization [J].

Bava, SV ;

Puliappadamba, VT ;

Deepti, A ;

Nair, A ;

Karunagaran, D ;

Anto, RJ .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (08) :6301-6308

[5] Polymeric nanoparticle-encapsulated curcumin (nanocurcumin"): A novel strategy for human cancer therapy" [J].

Bisht S. ;

Feldmann G. ;

Soni S. ;

Ravi R. ;

Karikar C. ;

Maitra A. ;

Maitra A. .

Journal of Nanobiotechnology, 5 (1)

[6] Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines [J].

Burich, Rebekah A. ;

Holland, William S. ;

Vinall, Ruth L. ;

Tepper, Clifford ;

White, Ralph W. deVere ;

Mack, Philip C. .

BJU INTERNATIONAL, 2008, 102 (10) :1458-1466

[7] Safety and anti-inflammatory activity of curcumin:: A component of tumeric (Curcuma longa) [J].

Chainani-Wu, N .

JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, 2003, 9 (01) :161-168

[8] Inhibition of cell survival signal protein kinase B/Akt by curcumin in human prostate cancer cells [J].

Chaudhury, LR ;

Hruska, KA .

JOURNAL OF CELLULAR BIOCHEMISTRY, 2003, 89 (01) :1-5

[9]

Cheng AL, 2001, ANTICANCER RES, V21, P2895

[10]

Cheng L, 2000, CLIN CANCER RES, V6, P1896

← 1 2 3 4 5 6 7 →